Moderna stock gains as COO appointment meets Nasdaq-100 entry
Published on 10/05/2026 at 21:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Moderna stock (ISIN US60770K1079) was trading at USD 203.09 on Nasdaq at 3:59 p.m. ET on October 5, 2026, up 6.88 percent from the prior close. The move coincides with Juan Andres starting as the company's chief operating officer and a scheduled Nasdaq-100 entry.
New COO starts oncology push
According to StockTitan on September 30, 2026, Moderna appointed Juan Andres to the newly created COO role effective October 5. He reports to CEO Stéphane Bancel, joins the Executive Committee and oversees manufacturing as Moderna prepares for a potential launch and scale-up of intismeran autogene.
The operating change arrives as the company broadens its portfolio. Moderna's infectious disease franchise now includes five approved vaccines, while the oncology pipeline remains tied to further clinical data and commercial execution.
Revenue remains small
Yahoo Finance reported that second-quarter 2026 revenue was USD 145 million, up 2 percent from the prior year, while the GAAP net loss was USD 782 million and GAAP loss per share was USD 1.97. The loss improved by USD 43 million, or 5 percent, from the year-earlier quarter.
That operating profile contrasts with the market value implied by the share price. Moderna's market capitalization stood at USD 80.6 billion on October 5, while the stock remained USD 5.81 below its 52-week high of USD 208.90, a gap of 2.78 percent.
Nasdaq-100 date is October 9
According to Nasdaq on October 1, 2026, Moderna will become a Nasdaq-100 component before market open on October 9, replacing Warner Bros. Discovery. The index change can create demand from products tracking the benchmark, but it does not alter Moderna's reported revenue or earnings profile.
MarketScreener listed a Hold mean consensus from 23 analysts on September 23, 2026, with an average price target of USD 119.56, a high target of USD 170.00 and a low target of USD 45.00. The figures frame the central tension around Moderna stock: index inclusion and oncology expectations have lifted the valuation while the latest quarterly loss remains substantial.
Moderna stock nears yearly high
Moderna stock was last at USD 203.09 on Nasdaq on October 5, 2026, with volume of 17,712,769 shares and a 52-week range of USD 22.28 to USD 208.90.
Moderna stock key facts
- Company: Moderna, Inc.
- ISIN: US60770K1079
- Ticker: MRNA
- Trading venue: Nasdaq
- Price (as of October 5, 2026, 3:59 p.m. ET): USD 203.09
- Market capitalization: USD 80.6 billion (as of October 5, 2026)
- 52-week range: USD 22.28-208.90 (as of October 5, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Index membership: Nasdaq-100 effective October 9, 2026
Upcoming dates for Moderna stock
- October 9, 2026: Nasdaq-100 inclusion before market open
- October 24, 2026: Investor event via webcast
